CMPS

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change -0.09
Percentage change -2.93	%

Peers: MNMD ATAI CYBN GHRS RLMD AXSM MNOV XENE PRTA CARA

| Held by: ARKG IBB PSIL SBIO BBC GWX BIB IBBQ

Index	-	P/E	-	EPS (ttm)	-2.30	Insider Own	6.39%	Shs Outstand	68.55M	Perf Week	-2.61%
Market Cap	204.28M	Forward P/E	-	EPS next Y	-1.45	Insider Trans	-37.78%	Shs Float	64.17M	Perf Month	-18.36%
Income	-155.14M	PEG	-	EPS next Q	-0.49	Inst Own	36.32%	Short Float	8.79%	Perf Quarter	-24.94%
Sales	0.00M	P/S	-	EPS this Y	22.76%	Inst Trans	30.29%	Short Ratio	4.72	Perf Half Y	-57.31%
Book/sh	2.26	P/B	1.32	EPS next Y	18.52%	ROA	-63.37%	Short Interest	5.64M	Perf Year	-66.82%
Cash/sh	2.41	P/C	1.23	EPS next 5Y	17.70%	ROE	-81.56%	52W Range	2.88 - 10.31	Perf YTD	-21.16%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-86.36%	52W High	-71.10%	Beta	2.33
Dividend TTM	-	Quick Ratio	5.92	Sales past 5Y	0.00%	Gross Margin	-	52W Low	3.47%	ATR (14)	0.28
Dividend Ex-Date	-	Current Ratio	5.92	EPS Y/Y TTM	3.88%	Oper. Margin	-	RSI (14)	33.40	Volatility	6.89% 7.93%
Employees	166	Debt/Eq	0.21	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	16.50
Option/Short	Yes / Yes	LT Debt/Eq	0.16	EPS Q/Q	-18.39%	Payout	-	Rel Volume	0.58	Prev Close	3.07
Sales Surprise	-	EPS Surprise	-0.57%	Sales Q/Q	-	Earnings	Feb 27 BMO	Avg Volume	1.19M	Price	2.98
SMA20	-14.83%	SMA50	-22.62%	SMA200	-45.51%	Trades		Volume	687,987	Change	-2.93%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-27-25	Initiated	Stifel	Buy	$11
Jul-23-24	Initiated	RBC Capital Mkts	Outperform	$23
Apr-01-24	Initiated	Morgan Stanley	Overweight	$30
Dec-12-23	Initiated	Deutsche Bank	Buy	$16
Nov-21-22	Resumed	Berenberg	Buy	$33
Nov-01-22	Initiated	Loop Capital	Buy	$34
Oct-29-21	Initiated	Oppenheimer	Outperform	$50
Jul-13-21	Initiated	Citigroup	Buy	$67
Jun-28-21	Initiated	Maxim Group	Buy	$70
May-11-21	Initiated	Cantor Fitzgerald	Overweight	$71
Apr-01-21	Initiated	ROTH Capital	Buy	$88
Oct-14-20	Initiated	H.C. Wainwright	Buy	$65
Oct-13-20	Initiated	Evercore ISI	Outperform
Oct-13-20	Initiated	Cowen	Outperform
Oct-13-20	Initiated	Canaccord Genuity	Buy	$80
Oct-13-20	Initiated	Berenberg	Buy	$50

Show Previous Ratings

Today 06:30AM	Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression (Business Wire)
Mar-22-25 10:30AM	Psychedelic: Exclusive talk with biotech company Clearmind Medicine (TipRanks)
Mar-21-25 11:50AM	Psychedelic: atai Life Sciences, NRx report quarterly results (TipRanks)
Mar-20-25 11:15AM	Lazard International Strategic Equity Portfolio Q4 2024 Commentary (SeekingAlpha)
05:35AM	Lazard International Equity Select Portfolio Q4 2024 Commentary (SeekingAlpha)
06:30AM	Loading…
Mar-18-25 06:30AM	Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression (Business Wire) -6.94%
Mar-11-25 06:30AM	Compass Pathways to Participate in Stifel Virtual CNS Forum (Business Wire)
Mar-05-25 11:06AM	Compass one of the most compelling stories in neuropsych, says H.C. Wainwright (TipRanks)
Mar-01-25 11:15AM	COMPASS Pathways plc (CMPS): Among the Best Psychedelic Stocks to Buy in 2025 (Insider Monkey)
Feb-28-25 11:30AM	Psychedelic: GH Research, Compass Pathways report earnings results (TipRanks)
02:11AM	Compass Pathways PLC (CMPS) Q4 2024 Earnings Call Highlights: Strategic Financing and R&D ... (GuruFocus.com)
Feb-27-25 03:15PM	Compass Pathways Plc (CMPS) Q4 2024 Earnings Call Transcript (Motley Fool) +5.95%
06:30AM	Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights (Business Wire)
Feb-25-25 04:00PM	Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-18-25 06:30AM	Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025 (Business Wire)
04:14PM	Loading…
Feb-13-25 04:14PM	It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care (Investor's Business Daily)
Feb-12-25 01:25PM	RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care. (Investor's Business Daily)
Feb-05-25 06:30AM	Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire) +5.50%
Jan-21-25 06:30AM	Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer (Business Wire)
Jan-10-25 07:01AM	Compass Pathways Announces Pricing of Underwritten Offering (Business Wire) -14.73%
Dec-18-24 06:30AM	Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI) (Business Wire) -6.43%
Nov-29-24 08:57PM	Is Your Mind Ready to Consider Investing in Psychedelics Stocks? (Motley Fool)
Nov-25-24 04:00PM	Compass Pathways to Participate in December Investor Conferences (Business Wire)
Nov-14-24 07:44AM	Compass Pathways to participate in Stifel 2024 Healthcare Conference (GlobeNewswire)
Nov-02-24 09:25AM	Compass Pathways cuts 30% of workforce on Phase 3 trial delays (TipRanks)
Nov-01-24 11:00AM	Compass Pathways PLC (CMPS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... (GuruFocus.com)
Oct-31-24 09:00PM	Compass Pathways Plc (CMPS) Q3 2024 Earnings Call Transcript (Motley Fool) -23.10%
08:03AM	Compass delays anticipated psilocybin readout, cuts staff (BioPharma Dive)
06:30AM	Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates (Business Wire)
Oct-24-24 06:30AM	Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024 (Business Wire)
07:00AM	Loading…
Sep-23-24 07:00AM	Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit (Business Wire)
Aug-28-24 06:00AM	Compass Pathways to participate in three investor conferences in September (GlobeNewswire)
Aug-25-24 09:06AM	Morgan Stanley Predicts up to 220% Jump for These 2 Strong Buy Stocks (TipRanks)
Aug-19-24 07:13AM	More promise for psilocybin in depression but safety remains a concern (Clinical Trials Arena)
Aug-12-24 12:47PM	FDA Rejection of MDMA Therapy Isnt End of Psychedelic-Drug Candidates (Barrons.com)
Aug-06-24 08:00AM	COMPASS Pathways to participate in Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire)
Aug-01-24 11:30PM	Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Transcript (Motley Fool) -9.83%
06:30AM	Compass Pathways announces second quarter 2024 financial results and business highlights (GlobeNewswire)
Jul-28-24 06:05PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jul-24-24 07:01AM	Compass Pathways to announce second quarter financial results on August 1, 2024 (GlobeNewswire)
Jul-11-24 07:00AM	3 Dirt-Cheap Drug Developers With Blockbuster Potential (InvestorPlace) +9.39%
Jul-08-24 07:45AM	3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers (InvestorPlace)
Jul-02-24 03:43PM	3 Psychedelic Stocks to Buy on the Dip: Summer 2024 (InvestorPlace)
Jun-26-24 06:30AM	Compass Pathways appoints Lori Englebert as Chief Commercial Officer (GlobeNewswire)
Jun-24-24 04:01PM	Compass Pathways to participate in upcoming H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire)
Jun-12-24 06:25AM	Should You Buy the Dip on Compass Pathways Stock? (Motley Fool) +7.04%
Jun-10-24 08:25AM	Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here's What You Need to Know. (Motley Fool) -5.62%
Jun-09-24 06:14PM	After FDA setback, psychedelic drugmakers distance themselves from a pioneer (Washington Post)
Jun-05-24 11:42AM	Psychedelic Drug Stocks Plummet On FDA Advisers' Doubts About Ecstasy Candidate (The Wall Street Journal)
May-21-24 08:05AM	These 2 Catalysts Could Soon Send Compass Pathways Stock Soaring (Motley Fool)
May-13-24 10:43AM	COMPASS Pathways plc (NASDAQ:CMPS) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 04:45AM	Compass Pathways Plc (CMPS) Q1 2024 Earnings Call Transcript (Motley Fool)
May-08-24 06:45AM	Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
06:30AM	Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder (GlobeNewswire)
May-03-24 04:58PM	Compass Pathways to announce first quarter financial results on May 8, 2024 (GlobeNewswire)
May-02-24 06:30AM	Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment (GlobeNewswire)
Apr-29-24 06:30AM	Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression (GlobeNewswire)
Apr-01-24 04:01PM	Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) +16.35%
Mar-31-24 05:47PM	20 Most Depressed Countries in Asia (Insider Monkey)
Mar-28-24 08:00AM	Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors (GlobeNewswire) -12.42%
Mar-19-24 08:00AM	The Next Great Biotech Boom Has Arrived (PR Newswire)
Mar-10-24 10:00AM	10 Alternatives to Antidepressant Medications (Insider Monkey)
Mar-05-24 09:59AM	15 Highest Paying Jobs with a Psychology Degree (Insider Monkey) -5.48%
08:52AM	20 Countries with Most Antidepressant Users in the World (Insider Monkey)
Mar-01-24 09:08AM	COMPASS Pathways plc (NASDAQ:CMPS) Q4 2023 Earnings Call Transcript (Insider Monkey) +11.78%
Feb-29-24 03:30PM	Compass Pathways Plc (CMPS) Q4 2023 Earnings Call Transcript (Motley Fool) -16.98%
07:34AM	Compass Pathways PLC Reports Increased Annual Net Loss Amid Clinical Advancements (GuruFocus.com)
07:00AM	Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Feb-27-24 12:33PM	Penny Power Players: 3 Stocks to Watch in the Microcap Arena (InvestorPlace) +9.64%
Feb-26-24 04:01PM	Compass Pathways to participate in upcoming TD Cowen investor conference (GlobeNewswire)
Feb-22-24 04:01PM	Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024 (GlobeNewswire)
Feb-21-24 03:06PM	Mental Health Mavericks: 3 Stocks Changing the Game (InvestorPlace)
Feb-19-24 07:00AM	Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen. (Motley Fool)
Feb-02-24 04:27PM	As investors pile into psychedelics, idealism gives way to pharma economics (Associated Press Finance)
Jan-31-24 04:01PM	Compass Pathways to participate in upcoming Oppenheimer investor conference (GlobeNewswire)
Jan-24-24 09:00AM	How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition (PR Newswire) +7.87%
Jan-16-24 08:00AM	Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved (GlobeNewswire)
Jan-09-24 01:56PM	Therapys New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution (InvestorPlace)
Jan-08-24 11:47AM	3 Big New Catalysts for Psychedelics Stocks in 2024 (Motley Fool) +11.07%
Jan-05-24 08:00AM	Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement (GlobeNewswire) -6.97%
Dec-29-23 08:42AM	5 Best Psychedelic Stocks to Buy (Insider Monkey)
Dec-19-23 04:05PM	Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder (GlobeNewswire) -5.87%
Dec-13-23 02:55PM	25 Best Online Psychology Degree Programs Heading Into 2024 (Insider Monkey) -6.62%
Dec-07-23 07:00AM	Compass Pathways appoints Teri Loxam as Chief Financial Officer (GlobeNewswire) +7.94%
Dec-06-23 04:00PM	Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry (GlobeNewswire)
Dec-05-23 04:09PM	Investing in Mental Health: 3 Stocks in the Wellness Space (InvestorPlace) -7.38%
Nov-24-23 08:00AM	Compass Pathways to participate in upcoming Evercore investor conference (GlobeNewswire) +6.61%
Nov-15-23 04:00AM	Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center (GlobeNewswire)
Nov-05-23 11:26AM	COMPASS Pathways plc (NASDAQ:CMPS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 11:39AM	Compass Pathways Plc (CMPS) Q3 2023 Earnings Call Transcript (Motley Fool) +7.73%
Nov-02-23 08:51AM	Compass Pathways PLC (CMPS) Reports Q3 2023 Financial Results and Business Highlights (GuruFocus.com)
07:00AM	COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Oct-29-23 05:17PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Oct-26-23 08:00AM	COMPASS Pathways announces CFO transition (GlobeNewswire)
Oct-24-23 04:01PM	COMPASS Pathways plc to Announce Third Quarter 2023 Financial Results on November 2, 2023 (GlobeNewswire) +6.86%
Oct-12-23 09:15AM	The Promise Of Psilocybin When It Comes To Mental Health, And How COMPASS Pathways (NASDAQ: CMPS) Is Advancing It (News Direct)
Oct-06-23 09:00AM	COMPASS Pathways Is Accelerating Patient Access To Evidence-Based Innovation In Mental Health Care (News Direct)
Sep-27-23 03:17PM	Dont Miss the Boom: 3 Psychedelic Stocks Set to Explode Higher (InvestorPlace)
Sep-22-23 08:30AM	How COMPASS Pathways Is Leveraging AI To Revolutionize The Mental Healthcare Space (News Direct)
Sep-19-23 09:25AM	One Year Into Kabir Naths Leadership, Compass Pathways (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing (News Direct)

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ATAI Life Sciences N.V.	10% Owner	Sep 26 '24	Sale	6.05	2,660,000	16,093,000	6,905,774	Sep 27 08:00 PM
Malievskaia Ekaterina	10% Owner	May 21 '24	Sale	7.91	8,900	70,379	3,931,687	May 22 04:22 PM
Malievskaia Ekaterina	10% Owner	May 21 '24	Sale	7.91	8,900	70,379	3,929,413	May 22 04:22 PM
Malievskaia Ekaterina	10% Owner	May 20 '24	Sale	7.89	6,704	52,908	3,938,313	May 22 04:22 PM
Malievskaia Ekaterina	10% Owner	May 20 '24	Sale	7.89	6,703	52,900	3,940,587	May 22 04:22 PM
Goldsmith George Jay	10% Owner	May 21 '24	Sale	7.91	8,900	70,379	3,929,413	May 22 04:21 PM
Goldsmith George Jay	10% Owner	May 21 '24	Sale	7.91	8,900	70,379	3,931,687	May 22 04:21 PM
Goldsmith George Jay	10% Owner	May 20 '24	Sale	7.89	6,704	52,908	3,938,313	May 22 04:21 PM
Goldsmith George Jay	10% Owner	May 20 '24	Sale	7.89	6,703	52,900	3,940,587	May 22 04:21 PM
Goldsmith George Jay	10% Owner	May 03 '24	Sale	8.82	18,762	165,456	3,947,290	May 06 06:31 PM
Goldsmith George Jay	10% Owner	May 03 '24	Sale	8.82	18,761	165,448	3,945,017	May 06 06:31 PM
Goldsmith George Jay	10% Owner	May 02 '24	Sale	8.29	9,622	79,768	3,963,778	May 06 06:31 PM
Goldsmith George Jay	10% Owner	May 02 '24	Sale	8.29	9,621	79,760	3,966,052	May 06 06:31 PM
Malievskaia Ekaterina	10% Owner	May 03 '24	Sale	8.82	18,762	165,456	3,947,290	May 06 06:30 PM
Malievskaia Ekaterina	10% Owner	May 03 '24	Sale	8.82	18,761	165,448	3,945,017	May 06 06:30 PM
Malievskaia Ekaterina	10% Owner	May 02 '24	Sale	8.29	9,622	79,768	3,963,778	May 06 06:30 PM
Malievskaia Ekaterina	10% Owner	May 02 '24	Sale	8.29	9,621	79,760	3,966,052	May 06 06:30 PM
Goldsmith George Jay	10% Owner	Apr 16 '24	Sale	8.53	23,881	203,679	3,986,523	Apr 18 04:12 PM
Goldsmith George Jay	10% Owner	Apr 16 '24	Sale	8.53	23,880	203,670	3,984,250	Apr 18 04:12 PM
Goldsmith George Jay	10% Owner	Apr 17 '24	Sale	8.78	10,850	95,307	3,973,400	Apr 18 04:12 PM
Goldsmith George Jay	10% Owner	Apr 17 '24	Sale	8.78	10,850	95,307	3,975,673	Apr 18 04:12 PM
Malievskaia Ekaterina	10% Owner	Apr 16 '24	Sale	8.53	23,881	203,679	3,986,523	Apr 18 04:10 PM
Malievskaia Ekaterina	10% Owner	Apr 16 '24	Sale	8.53	23,880	203,670	3,984,250	Apr 18 04:10 PM
Malievskaia Ekaterina	10% Owner	Apr 17 '24	Sale	8.78	10,850	95,307	3,975,673	Apr 18 04:10 PM
Malievskaia Ekaterina	10% Owner	Apr 17 '24	Sale	8.78	10,850	95,307	3,973,400	Apr 18 04:10 PM
Goldsmith George Jay	10% Owner	Apr 01 '24	Sale	8.96	25,750	230,666	4,008,130	Apr 02 04:23 PM
Goldsmith George Jay	10% Owner	Apr 01 '24	Sale	8.96	25,750	230,666	4,010,404	Apr 02 04:23 PM
Malievskaia Ekaterina	10% Owner	Apr 01 '24	Sale	8.96	25,750	230,666	4,010,404	Apr 02 04:22 PM
Malievskaia Ekaterina	10% Owner	Apr 01 '24	Sale	8.96	25,750	230,666	4,008,130	Apr 02 04:22 PM
Malievskaia Ekaterina	10% Owner	Mar 28 '24	Sale	8.65	25,750	222,776	4,036,154	Apr 01 08:55 AM
Malievskaia Ekaterina	10% Owner	Mar 28 '24	Sale	8.65	25,750	222,776	4,033,880	Apr 01 08:55 AM
Goldsmith George Jay	10% Owner	Mar 28 '24	Sale	8.65	25,750	222,776	4,033,880	Apr 01 08:55 AM
Goldsmith George Jay	10% Owner	Mar 28 '24	Sale	8.65	25,750	222,776	4,036,154	Apr 01 08:55 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Compass Pathways Plc ADR

Upgrade your FINVIZ experience